These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 32077352)
1. Spontaneous remission and clonal evolution in lenalidomide associated secondary AML. Waller DD; Monczak Y; Michel RP; Shustik C; Sebag M Leuk Lymphoma; 2020 Jul; 61(7):1724-1727. PubMed ID: 32077352 [No Abstract] [Full Text] [Related]
2. Single-cell mutational profiling enhances the clinical evaluation of AML MRD. Ediriwickrema A; Aleshin A; Reiter JG; Corces MR; Köhnke T; Stafford M; Liedtke M; Medeiros BC; Majeti R Blood Adv; 2020 Mar; 4(5):943-952. PubMed ID: 32150611 [TBL] [Abstract][Full Text] [Related]
3. Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. Bansal D; Vij K; Chang GS; Miller CA; DiPersio JF; Vij R; Heath SE; Westervelt P; Welch JS; Fehniger TA Haematologica; 2018 Jun; 103(6):e270-e273. PubMed ID: 29567774 [No Abstract] [Full Text] [Related]
4. Clonal evolution of acute myeloid leukemia from diagnosis to relapse. Vosberg S; Greif PA Genes Chromosomes Cancer; 2019 Dec; 58(12):839-849. PubMed ID: 31478278 [TBL] [Abstract][Full Text] [Related]
6. Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia. Rothenberg-Thurley M; Amler S; Goerlich D; Köhnke T; Konstandin NP; Schneider S; Sauerland MC; Herold T; Hubmann M; Ksienzyk B; Zellmeier E; Bohlander SK; Subklewe M; Faldum A; Hiddemann W; Braess J; Spiekermann K; Metzeler KH Leukemia; 2018 Jul; 32(7):1598-1608. PubMed ID: 29472724 [TBL] [Abstract][Full Text] [Related]
7. AML evolution from preleukemia to leukemia and relapse. Shlush LI; Mitchell A Best Pract Res Clin Haematol; 2015; 28(2-3):81-9. PubMed ID: 26590763 [TBL] [Abstract][Full Text] [Related]
8. Clonal evolution and devolution after chemotherapy in adult acute myelogenous leukemia. Parkin B; Ouillette P; Li Y; Keller J; Lam C; Roulston D; Li C; Shedden K; Malek SN Blood; 2013 Jan; 121(2):369-77. PubMed ID: 23175688 [TBL] [Abstract][Full Text] [Related]
9. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Uy GL; Duncavage EJ; Chang GS; Jacoby MA; Miller CA; Shao J; Heath S; Elliott K; Reineck T; Fulton RS; Fronick CC; O'Laughlin M; Ganel L; Abboud CN; Cashen AF; DiPersio JF; Wilson RK; Link DC; Welch JS; Ley TJ; Graubert TA; Westervelt P; Walter MJ Leukemia; 2017 Apr; 31(4):872-881. PubMed ID: 27740633 [TBL] [Abstract][Full Text] [Related]
10. The priming induction regimen of HAG as a low dose chemotherapy strategy in AML clonal evolution. Chen A; Yang J; Hu S; Wang QF Sci China Life Sci; 2015 Dec; 58(12):1302-5. PubMed ID: 26588914 [No Abstract] [Full Text] [Related]